PD-L1 IHC (SP142) Analysis
The VENTANA PD-L1 (SP142) Assay is a crucial tool in the field of cancer diagnostics and immunotherapy. It employs a qualitative immunohistochemical approach, utilizing a specialized rabbit monoclonal anti-PD-L1 antibody (clone SP142) to assess the presence of programmed death-ligand 1 (PD-L1) protein in both tumor cells and immune cells within formalin-fixed, paraffin-embedded (FFPE) tissues. This assay is particularly noteworthy as it holds the distinction of being the first and only CE-IVD marked test for TECENTRIQ in triple-negative breast cancer (TNBC) patients.
The FDA has granted accelerated approval for the use of Atezolizumab (TECENTRIQ®) in combination with nab-paclitaxel for adult patients suffering from unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1. The determination of PD-L1 expression is facilitated by an FDA-approved test, where the VENTANA PD-L1 (SP142) Assay plays a pivotal role as a companion diagnostic device. This assay contributes significantly to the personalized treatment of TNBC patients, ensuring that they receive the most appropriate therapeutic interventions based on their unique PD-L1 expression profiles.
Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.
.png){kind=small}
YES 
NO 
